Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 9649-9656

  Urbschat, Anja ^a   Stumpf, Svenja ^a   Hänze, Jörg ^a   Paulus, Patrick ^b   Maier, Thorsten J ^c   Weipert, Christine ^d   Hofmann, Rainer ^a   Hegele, Axel ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

^c AARHUS UNIVERSITY   (Denmark)

^d Clinic of Urology and Andrology Landeskrankenhaus Hall in Tirol   (Austria)

Author keywords

Clear cell renal cell carcinoma; JAK2; SOCS3; STAT3

Indexed keywords

CARBONATE DEHYDRATASE IX; GAMMA INTERFERON; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR 1; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; JANUS KINASE 2; MESSENGER RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; SOCS3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RENAL CELL CARCINOMA CELL LINE; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; GENETICS; INFLAMMATION; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTERLEUKIN-6; INTERLEUKINS; MALE; MIDDLE AGED; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN;

EID: 84955249274     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4857-9     Document Type: Article

References (31)

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–386.
2. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.
3. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.
4. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.
5. Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, et al. Japan Immunotherapy S-SGfKC: Stat3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur Urol. 2013;63:745–52.
6. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. Stat3 inhibitor wp1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102:1592–9.
7. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762–5.
8. Darnell Jr JE. Stats and gene regulation. Science. 1997;277:1630–5.
9. Yoshimura A, Naka T, Kubo M. Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.
10. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. Socs-3 inhibits il-12-induced stat4 activation by binding through its sh2 domain to the stat4 docking site in the il-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.
11. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J Exp Med. 2001;193:471–81.
12. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator socs3/cis3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–8.
13. Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, et al. Suppressors of cytokine signaling regulate fc receptor signaling and cell activation during immune renal injury. J Immunol. 2004;172:6969–77.
14. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. Socs-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133–8.
15. Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of socs-1 and socs-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol 2014.
16. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the socs3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179–93.
17. Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of cxc-chemokine receptor cxcr2 and suppressor of cytokine signaling-3 (socs-3) in renal cell carcinoma. BMC Cancer. 2014;14:149.
18. Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58:333–6.
19. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 2007;100:556–60.
20. Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.
21. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.
22. Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled il-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:369–76.
23. Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not erks, mediates the il-6-induced proliferation of renal cancer cells, achn and 769p. Kidney Int. 2002;61:926–38.
24. Yu H, Pardoll D, Jove R. Stats in cancer inflammation and immunity: a leading role for stat3. Nat Rev Cancer. 2009;9:798–809.
25. Si H, Banga RS, Kapitsinou P, Ramaiah M, Lawrence J, Kambhampati G, et al. Human and murine kidneys show gender- and species-specific gene expression differences in response to injury. PLoS ONE. 2009;4:e4802.
26. Neuwirt H, Eder IE, Puhr M, Rudnicki M. Socs-3 is downregulated in progressive ckd patients and regulates proliferation in human renal proximal tubule cells in a stat1/3 independent manner. Lab Investig. 2013;93:123–34.
27. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.
28. Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of stat3 in renal tumors. Am J Transl Res. 2009;1:283–90.
29. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.
30. Wolk K, Sabat R. Interleukin-22: a novel t- and nk-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.
31. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. Il-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.